Sage Journals: Discover world-class research

Abstract

The World Health Organization declared the severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 virus outbreak as a pandemic on May 27, 2020. Since then, more than 5 488 825 cases across the world have been recorded at the time of revising this article. Governments around the world have imposed serious containment measures, meanwhile, the healthcare system is overburdened due to large increases in COVID-19 cases. However, no specific anti-SARS-CoV-2 virus drugs or vaccines have yet been shown to be effective to fight this causative virus of acute infectious pneumonia. The current review was conducted to look for potential natural and synthesized drugs for the treatment of COVID-19 patients. Previously published data in journals, textbooks, periodicals, websites, and sources, including data about the treatment of human coronavirus with natural and synthesized drugs, were taken from the online bibliographical databases. The results showed that syndic drugs approved for other human diseases have been used to improve the symptoms of patients infected with SARS-CoV-2. Several clinical trials across the world evidenced beneficial effects of natural and synthesized drugs in the treatment of SARS-CoV-2 infections. On the other hand, many studies have provided a deep understanding of the therapeutic effects of conventional and traditional medicine in identifying naturally occurring drugs effective against the SARS-CoV-2 virus. Both natural and synthesized drugs should come together to fight the SARS-CoV-2 virus and other potential emerging dangerous viral diseases since they have shown promising findings in clinical trials conducted with COVID-19 patients.

Keywords

COVID-19 conventional medicine traditional medicine coronavirus pneumonia

COVID-19, also known as 2019-nCoV and severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 virus, belongs to the family Coronaviridae. As SARS-CoV-2 belongs to the genus Betacoronavirus, it is closely related to MERS-CoV and SARS-CoV and thus is a positive-strand RNA virus with the largest viral genome of all RNA viruses which have been reported to cause severe symptoms of pneumonia in previous pandemics.¹ The genetic structure of SARS-CoV-2 virus has been characterized and previously published.^2,3 The main proteins in this virus and those previously identified in SARS-CoV and MERS-CoV showed a high similarity between them. Coronavirus infection is commonly induced by the virus rapidly integrating its genetic material into the host cell and multiplying, depending on the host organism for its development.⁴

The first research on human coronaviruses (HCoVs) was carried out in the mid-1960s.⁵ After 40 years a CoV was declared as the responsible agent for SARS, which caused a global health burden.⁶ The novelty of this strain of virus means that many uncertainties are surrounding its behavior, and, therefore, it is too early to determine natural and synthetic drugs that could contribute to society as prophylactic agents or as suitable substances as anti-coronavirus drugs against COVID-19 virus. However, due to the high similarity between the COVID-19 virus and the previously reported SARS-CoV and MERS-CoV viruses, previously published research on natural compounds proven to exert anti-coronavirus effects may be a valuable guide to finding natural agents which may be active against the SARS-CoV-2 virus.

Currently, COVID-19 disease cases are growing very quickly worldwide.⁷ In the United States, Brazil, Spain, Italy, and other countries, the COVID-19 pandemic is overburdening the healthcare system.⁸ In real time, even though a series of potential drugs have been reported to improve the disease, there are no approved or recommended antiviral drugs for COVID-19.

To contribute to society as prophylactic agents against COVID-19, the current review was undertaken to look for the potential for the intervention of both synthetic and natural drugs to fight COVID-19.

Material and Methods

Data Collection

Previously published data in journals, textbooks, periodicals, websites reporting the treatment of coronavirus with conventional and traditional medicine were taken from the online bibliographical databases such as Google, Google Scholar, PubMed, Science Direct, and Springer Link. These data were searched using keywords related to natural and synthesized drugs used in coronavirus treatment. A list was established as a table including the medicinal plants declared to be used in the treatment of coronavirus around the world. The consulted sources were also searched for pharmacological studies giving supportive information on the detail of the involved plants such as the responsible compound classes as well as the mechanism of action.

Results and Discussion

Evidence of Conventional Treatment of Human Coronaviruses

Although there is active research to develop efficient drugs to fight COVID-19, no specific antiviral therapeutics have been developed, and the main adopted treatment strategy is a combination of antibiotics, antivirals, corticosteroids, and convalescent plasma from recovered patients.⁹ COVID-19 patients have been treated with a combination of antibiotics and the HIV protease inhibitors ritonavir and lopinavir.¹⁰ Ribavirin, an analog of ritonavir,¹¹ may present promising efficacy on COVID-19 since this drug was used in the treatment of the respiratory syncytial virus. Moreover, ribavirin was approved for treating the SARS and MERS outbreak.^11
-13 However, earlier data reported that ribavirin induced severe secondary effects such as anemia; its efficacy on SARS-CoV-2 was also not clear.¹² The RNA polymerase of RNA viruses, such as the influenza virus, may be inhibited by the nucleoside analog favipiravir.¹⁴ Literature shows that it possessed an anti-SARS-CoV-2 effect, but its in vivo efficacy was elusive. Remdesivir could be a promising treatment for the treatment of COVID-19 patients. This drug showed in vitro and in vivo effects on an array of RNA viruses including SARS as well as MERS¹⁵ and reduced viral loads sufficiently in treated animals.¹⁶ As reported earlier, remdesivir had a significant effect on SARS-CoV-2 in Vero E6 cells, and patients affected by SARS-CoV-2 recovered after they received remdesivir intravenously.^10,17 At present, remdesivir is under clinical trial assessment for COVID-19 patients.¹⁸ Even though oseltamivir has been used to treat COVID-19 patients, its efficacy has not been confirmed.¹⁰

Other drugs previously approved for the treatment of human diseases have been tested against SARS-CoV-2, which may lead to a potential treatment for COVID-19 patients. Chloroquine and hydroxychloroquine showed potential broad-spectrum antiviral effects on SARS-CoV-2,¹⁹ and their efficacy is currently under clinical trials. Available data have recommended the use of IFNα atomization inhalation to treat COVID-19 patients,⁹ and clinical trials have been conducted on the potential of IFNα-2b treatment of COVID-19 since it was approved to treat HCV infection.²⁰ However, its efficacy has not been well shown. Earlier published data showed that corticosteroids were used to reduce the cytokine elevation in patients affected by SARS-CoV²¹ as well as MERS-CoV.^22,23 However, the effect on these patients was unclear, and the clearance of the viruses was delayed by the treatment with corticosteroids.^24,25 Corticosteroids have not been recommended for systematic use in the treatment of COVID-19 patients.

Convalescent plasma could be a promising tool to fight COVID-19 since it significantly decreased the viral load in severe influenza and SARS-CoV patients and, therefore, reduced the mortality.^24,26 COVID-19 patients treated with convalescent plasma in China showed promising results, although the efficacy needs further evaluation ¹⁶.

Medicinal Plants or Their Constituents for the Treatment of Coronavirus Infection

Since natural products have been used to treat infectious diseases for many years, there is potential for the intervention of such products for the complementary or alternative treatment of coronavirus infection. Literature from across the world has reported the history of the intervention of traditional medicine in the treatment of coronavirus infection that occurred in humans and animals. Plant products or their constituents could be a promising weapon for the treatment of COVID-19 since early patients with SARS-CoV infection have benefited from alternative medicine (Table 1).

Table 1

Medicinal Plants Used for the Treatments of Coronavirus Infection.

Plant name/family	a—Plant part b—Method of extraction c—Concentration	Mode of action	Year of study	Targeted virus	Reference
Sophora flavescens Ait. Fabaceae	a—Sophorae radix b—Methanolic extraction/sonication (3 h) c—Doses tested: 25, 50, 75, and 100 mg/mL of the extract	Decrease of intracellular viral RNA levels, MHV-A59, viral proteins production, and viral replication	2010	MHV-A59, PEDV	²⁷
Sanguisorba officinalis L. Rosaceae	a—Sanguisorbae radix b—Methanolic extraction/sonication (3 h) c—Doses tested: 25, 50, 75, and 100 mg/mL of the extract	Decrease of coronavirus production and protein synthesis levels	2010	MHV-A59, PEDV	²⁷
Acanthopanax gracilistylus W.W.Sm. Araliaceae	a—Dried root barks b—Methanolic extraction/sonication (3 h) c—Doses tested: 25, 50, 75, and 100 mg/mL of the extract	Induction of cyclooxygenase-2 expression via the activation of ERK and p38	2010	MHV-A59	²⁷
Tylophora indica (Burm.f.) Merr. Apocynaceae	a—Leaves b—Methanol extract c—Concentrations tested: 30-1000 nM	Tylophorine compounds inhibited the TGEV-induced apoptosis and subsequent cytopathic effect in ST cells and blocked the TGEV replication	2010	TGEV	²⁸
Cimicifuga racemosa (L.) Nutt. Ranunculaceae	a—Cimicifuga rhizoma b—No data c—No data	Decrease of PEDV levels and can have a potent anti-coronaviral effect	2020	PEDV	²⁹
Melia azedarach L. Meliaceae	a—Meliae cortex b—No data c—No data	Decrease of PEDV levels and can have a potent anti-coronaviral effect	2020	PEDV	²⁹
Coptis chinensis Franch Ranunculaceae	a—Coptidis rhizome b—No data c—No data	PEDV has a potent anti-coronaviral effect	2020	PEDV	²⁹
Litchi chinensis Sonn. Sapindaceae	a—Seeds b—Flavonoids extract c—No data	Flavonoids extracted from the litchi seeds have an important effect on SARS-CoV3CL symptoms by inhibiting the proteinase activity which is essential for viral protein synthesis	2020	SARS-CoV3CL	²⁹
Camellia japonica L. Theaceae	a—Flowers b—Oleanane triterpenes extract c—10, 8, 2, and 1 µM	Coumarins from Saposhnikovia divaricata, oleanane, triterpenes from Camellia japonica L., and phloroglucinols from Dryopteris crassirhizoma exerted potential inhibitory effects on PEDV replication by inhibition of viral replication	2016	PEDV	³⁰
Saposhnikovia divaricata (Turcz.) Schischk. Apiaceae	a—Radix b—Coumarins extract c—10, 8, 2, and 1 µM		2016	PEDV	³⁰
Dryopteris crassirhizoma Nakai Dryopteridaceae	a—Rhizomes b—Phloroglucinols c—10, 8, 2, and 1 µM		2016	PEDV	³⁰
Scrophularia scorodonia L. Scrophulariaceae	a—No data b— Saikosaponins (A, B2, C, and D) c—Concentrations: 0, 2.5, 25, and 250 mmol/L	Saikosaponins (A, B2, C, and D) have anti-HCoV-229E activity and saikosaponin B2 possesses the strongest effect	2006	HCoV	³¹
Cimicifuga racemosa (L.) Nutt. Ranunculaceae	a—Rhizomes b—Methanolic extract/ultrasonic conditions c—concentration tested: 100 µg/mL	Reduction of the MHV production and the intracellular viral RNA, protein expression, and PEDV production	2008	MHV-A59, PEDV	³²
Melia azedarach L. Meliaceae	a—Cortex b—Methanolic extract/ultrasonic conditions c—Concentration tested: 100 µg/mL		2008	MHV-A59, PEDV	³²
Coptis chinensis Franch Ranunculaceae	a—Rhizomes b—Methanolic extract/ultrasonic conditions c—Concentration tested: 100 µg/mL		2008	MHV-A59, PEDV	³²
Phellodendron chinense Schneid Rutaceae	a—Cortex b—Methanolic extract/ultrasonic conditions c—Concentration tested: 100 µg/mL		2008	MHV-A59, PEDV	³²
Sophora subprostrata L. Fabaceae	a—Radix b—Methanolic extract/ultrasonic conditions c—Concentrations tested: 100 µg/mL		2008	MHV-A59, PEDV	³²
Juniperus formosana Hayata Cupressaceae	a—Heartwood b— Abietane-type diterpenoids (isolated compound) c— Concentrations tested: 0.1-10 µM	Abietane-type diterpenoids possess important anti-SARS-CoV effects	2007	SARS-CoV	³³
Chamaecyparis obtusa (Siebold & Zucc.) Endl. Cupressaceae	a—Heartwood b—Savinin (purified molecule) c— Concentrations tested: 0.1-10 µM	Savinin and betulinic acid are competitive inhibitors of SARS-CoV3CL protease	2007	SARS-CoV	³³
Compounds from several medicinal plants	a—No data b— Apigenin-7-glucoside, catechin, luteolin-7-glucoside, demethoxycurcumin, oleuropein, epicatechin-gallate curcumin c—No data	Potent inhibitors of COVID-19 Mpro	2020	COVID-19	³⁴
Euphorbia neriifolia L. Euphorbiaceae	a—Leaves b—Ethanolic extract c—No data	The triterpenoid 3β-friedelanol exerted the potent antiviral effect than the positive control (actinomycin D)	2012	HCoV	³⁵
Isatis indigotica Fortune ex Lindl. Brassicaceae	a—Root b—Emodin and hesperetin (purified compounds) c—Concentrations tested: from 1 to 500 µg/mL	Hesperetin and aloe-emodin inhibited the cleavage activity of 3C-like protease (3CLpro) of SARS-CoV	2005	SARS-CoV	³⁶
Galla chinensis L. Anacardiaceae	a—No data b—Tetra-O-galloyl-d-glucose c—Concentrations tested: 10^-3 to 10^-7 mol/L	Tetra-O-galloyl-d-glucose from Galla chinensis inhibits the entry process of SARS-CoV into host cells	2004	SARS-CoV	³⁷
Veronica linariifolia Pall. ex Link Plantaginaceae	a—No data b—Luteolin c—Concentrations tested: 10^-3 to 10^-7 mol/L	Luteolin inhibits the SARS-CoV	2004	SARS-CoV	³⁷
Morus alba L. Moraceae	a—No data b—No data c—Concentrations tested: 0-400 µg/mL	The herbal formula (KDBFD) transiently modulated the human immune system	2011	SARS-CoV	³⁸
Chrysanthemum Morifolium Ramat. Asteraceae	a—No data b—No data c—Concentrations tested: 0-400 µg/mL		2011	SARS-CoV	³⁸
Forsythia suspensa (Thunb.) Vahl Oleaceae	a—No data b—No data c—Concentrations tested: 0-400 µg/mL		2011	SARS-CoV	³⁸
Platycodon grandiflorum (Jacq.) A. DC Campanulaceae	a—Radix b—No data c—Concentrations tested: 0-400 µg/mL		2011	SARS-CoV	³⁸
Glycyrrhiza uralensis Fisch. ex DC. Fabaceae	a—Radix b—No data c—Concentrations tested: 0-400 µg/mL		2011	SARS-CoV	³⁸
Scutellaria baicalensis Georgi Lamiaceae	a—Radix b—No data c—Concentrations tested: 0-400 µg/mL		2011	SARS-CoV	³⁸
Saposhnikovia divaricata (Turcz. ex Ledeb.) Schischk. Apiaceae	a—Radix b—No data c—Concentrations tested: 0-400 µg/mL		2011	SARS-CoV	³⁸
Houttuynia cordata Thunb Saururaceae	a—No data b—No data c—IC₅₀ = 251.1 µg/mL	Immunostimulatory and antiviral effects	2011	SARS-CoV	³⁸
Ganoderma lucidum (Curtis ex Fr.) P. Karst. Ganodermataceae	a—No data b—No data c—IC₅₀ = 41.9 µg/mL	Ganoderma lucidum inhibited SARS-CoV RNA-dependent RNA polymerase	2011	SARS-CoV	³⁸
Compounds from several medicinal plants	a—No data b—Flavonoids c—No data	Kaempferol glycosides are good candidates for 3a channel proteins of coronaviruses	2014	SARS-CoV	³⁹
Rheum officinale Baill. Polygonaceae	a—Root tubers b—Ethanolic extract c—Concentrations 0.1-100 µg/mL	Emodin, an anthraquinone compound, blocked the binding of SARS-CoV S protein to ACE2 and the infectivity of S protein-pseudotyped retrovirus to Vero E6 cells	2007	SARS-CoV	⁴⁰
Toona sinensis (Juss.) M. Roem. Meliaceae	a—Leaf b—Water extract c—Concentrations tested: 5, 20, 50, and 200 µg/mL	Tender leaf extract of Toona sinensis was found to have an important effect on SARS-CoV but the action mode of Toona sinensis Roem. to inhibit SARS-CoV remains unclear	2008	SARS-CoV	⁴¹
Rheum palmatum L. Polygonaceae	a—Rhizomes b—Alcoholic extract c—Concentrations tested: 100, 50, 25, 12.5, 6.25, 3.12, and 1.56 µg/mL	Rheum palmatum L. was found to inhibit 3 CL protease activity, as already known that the activity of 3C-like proteases is inhibited, SARS-CoV replication in the host cell will be also inhibited	2009	SARS-CoV	⁴²
Compounds from several medicinal plants	a—No data b—Flavonoids c—Concentrations tested: 0.5-2.5 µM	Pectolinarin, rhoifolin, and herbacetin blocked the enzymatic activity of 3C-like protease and as a result SARS-CoV replication	2020	SARS-CoV	⁴³
Compounds from several medicinal plants	a—No data b—Water extract c—Concentrations tested: 0-60 µM	Quercetin, epigallocatechin gallate, and gallocatechin gallate inhibited 3C-like protease of SARS-CoV (the 3C-like protease of a SARS-associated coronavirus (SARS‐CoV) is vital for SARS-CoV replication)	2012	SARS-CoV	⁴⁴
Chromadex	a—No data b—No data c—Concentrations tested: 0.01, 0.1, 1, and 10 µM	Myricetin and scutellarein inhibited SARS-CoV helicase protein by affecting the ATPase activity	2012	SARS-CoV	⁴⁵
Scutettaria baicalensis L. Lamiaceae	a—No data b—No data c—Concentrations tested: 0.01, 0.1, 1, and 10 µM		2012	SARS-CoV	⁴⁵
Stephania tetrandra S. Moore Menispermaceae	a—No data b—No data c— Concentrations tested: 0.2, 1, and 5 µM	bis-Benzylisoquinoline alkaloids—tetrandrine, cepharanthine, and fangchinoline—suppressed the replication of HCoV-OC43 and inhibited viral S and N protein expression	2019	HCoV	⁴⁶
Pyrrosia lingua (Thunb.) Farw. Polypodiaceae	a—Leaf b—Chloroform extract c—EC50 = 43.22 µg/mL	The herbal formula induced significant inhibition effects on SARS-CoV-induced cytopathic effect	2005	SARS-CoV	⁴⁷
Artemisia annua L. Compositae	a—Whole plant b—Ethanolic extract c—EC50 = 34.52 µg/mL		2005	SARS-CoV	⁴⁷
Lindera aggregata (Sims) Kosterm. Lauraceae	a—Root b—Ethanolic extract c—EC50 = 88.2 µg/mL		2005	SARS-CoV	⁴⁷
Lycoris radiata Miq. Amaryllidaceae	a—Stem cortex b—Ethanolic extract c—EC50 = 2.4 µg/mL		2005	SARS-CoV	⁴⁷
Cladastris lutea L. Fabaceae	a—No data b—Glucose c—Concentrations tested: 640, 256, 120, and 41 µg/mL		2007	SARS-CoV	⁴⁷
Artocarpus integrifolia L. Moraceae	a—No data b—Galactose c—Concentrations tested: 640, 256, 120, and 41 µg/mL		2007	SARS-CoV	⁴⁷
Phragmites australis (Cav.) Trin. ex Steud. Gramineae	a—No data b—N-acetyl glucosamine c—Concentrations tested: 640, 256, 120, and 41 µg/mL		2007	SARS-CoV	⁴⁷

ERK, extracellular signal-related kinase; HCoV, human coronavirus; MHV-A59, mouse hepatitis virus A59; PEDV, porcine epidemic diarrheavirus; SARS-CoV, severe acute respiratory syndrome coronavirus; TGEV, transmissible gastroenteritis coronavirus.

Conclusion

The current review summarizes a range of natural and synthesized products that have been shown previously to have beneficial antiviral properties and may have potential as prophylactic agents against COVID-19. Further studies involving both traditional and conventional medicine may lead to identifying novel agents that could be promising weapons to fight COVID-19 or any other potential emerging dangerous viral diseases. The safety of traditional medicine in the treatment of COVID-19 patients has not been investigated in the current work, and, therefore, the toxicological assessment of any natural medicine would need to be meticulously evaluated. Any potential toxicity or interference of the product with either traditional or conventional medicine induced by herb-drug interaction should be understood.

Footnotes

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Mohammed Bourhia

References

Dijkman

van der Hoek

. Human coronaviruses 229E and NL63: close yet still so far. J Formos Med Assoc. 2009;108(4):270-279.doi:10.1016/S0929-6646(09)60066-8

http://www.ncbi.nlm.nih.gov/pubmed/19369173

Zhou

Yang

X-L.

Wang

X-G

et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273.doi:10.1038/s41586-020-2012-7

http://www.ncbi.nlm.nih.gov/pubmed/32015507

Andersen

KG.

Rambaut

Lipkin

WI.

Holmes

EC.

Garry

. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450-452.doi:10.1038/s41591-020-0820-9

http://www.ncbi.nlm.nih.gov/pubmed/32284615

Zhang

D-H.

K-L.

Zhang

Deng

S-Q.

Peng

. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. J Integr Med. 2020;18(2):152-158.doi:10.1016/j.joim.2020.02.005

http://www.ncbi.nlm.nih.gov/pubmed/32113846

Sastre

Dijkman

Camuñas

et al. Differentiation between human coronaviruses NL63 and 229E using a novel double-antibody sandwich enzyme-linked immunosorbent assay based on specific monoclonal antibodies. Clin Vaccine Immunol. 2011;18(1):113-118.doi:10.1128/CVI.00355-10

http://www.ncbi.nlm.nih.gov/pubmed/21084464

Y-S.

Lin

W-H.

Hsu

JT-A.

Hsieh

H-P

. Antiviral drug discovery against SARS-CoV. Curr Med Chem. 2006;13(17):2003-2020.doi:10.2174/092986706777584988

http://www.ncbi.nlm.nih.gov/pubmed/16842194

Dong

Gardner

. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-534.doi:10.1016/S1473-3099(20)30120-1

http://www.ncbi.nlm.nih.gov/pubmed/32087114

Remuzzi

. COVID-19 and Italy: what next? The Lancet. 2020;395(10231):1225-1228.doi:10.1016/S0140-6736(20)30627-9

Jin

Y-H.

Cai

Cheng

Z-S

et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):1-23.doi:10.1186/s40779-020-0233-6

10.

Chen

Zhou

Dong

et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.doi:10.1016/S0140-6736(20)30211-7

http://www.ncbi.nlm.nih.gov/pubmed/32007143

11.

De Clercq

. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-150.doi:10.1038/d41573-020-00016-0

32127666

12.

Jordan

PC.

Stevens

SK.

Deval

. Nucleosides for the treatment of respiratory RNA virus infections. Antivir Chem Chemother. 2018;26(2040206618764483):1-19.doi:10.1177/2040206618764483

http://www.ncbi.nlm.nih.gov/pubmed/29562753

13.

Zumla

Chan

JFW.

Azhar

EI.

Hui

DSC.

Yuen

K-Y

. Coronaviruses — drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327-347.doi:10.1038/nrd.2015.37

http://www.ncbi.nlm.nih.gov/pubmed/26868298

14.

De Clercq

. Highlights in the development of new antiviral agents. Mini Rev Med Chem. 2002;2(2):163-175.doi:10.2174/1389557024605474

http://www.ncbi.nlm.nih.gov/pubmed/12370077

15.

Sheahan

TP.

Sims

AC.

Graham

et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653-20.doi:10.1126/scitranslmed.aal3653

http://www.ncbi.nlm.nih.gov/pubmed/28659436

16.

Zhang

Liu

. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol. 2020;92(5):479-490.doi:10.1002/jmv.25707

http://www.ncbi.nlm.nih.gov/pubmed/32052466

17.

Holshue

ML.

DeBolt

Lindquist

et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929-936.doi:10.1056/NEJMoa2001191

http://www.ncbi.nlm.nih.gov/pubmed/32004427

18.

Lai

C-C.

Shih

T-P.

W-C.

Tang

H-J.

Hsueh

P-R

. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924 doi:10.1016/j.ijantimicag.2020.105924

http://www.ncbi.nlm.nih.gov/pubmed/32081636

19.

Colson

Rolain

J-M.

Lagier

J-C.

Brouqui

Raoult

. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932-105933.doi:10.1016/j.ijantimicag.2020.105932

http://www.ncbi.nlm.nih.gov/pubmed/32145363

20.

Habibzadeh

Stoneman

. The novel coronavirus: a bird's eye view. Int J Occup Environ Med. 2020;11(2):1921-1965.doi:10.15171/ijoem.2020.1921

http://www.ncbi.nlm.nih.gov/pubmed/32020915

21.

Ding

Zhang

et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol. 2006;210(3):288-297.doi:10.1002/path.2067

http://www.ncbi.nlm.nih.gov/pubmed/17031779

22.

Faure

Poissy

Goffard

et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One. 2014;9(2):e88716 doi:10.1371/journal.pone.0088716

http://www.ncbi.nlm.nih.gov/pubmed/24551142

23.

Falzarano

de Wit

Rasmussen

et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313-1317.doi:10.1038/nm.3362

http://www.ncbi.nlm.nih.gov/pubmed/24013700

24.

Stockman

LJ.

Bellamy

Garner

. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343-1531.doi:10.1371/journal.pmed.0030343

http://www.ncbi.nlm.nih.gov/pubmed/16968120

25.

Arabi

YM.

Mandourah

Al-Hameed

et al. Corticosteroid therapy for critically ill patients with middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757-767.doi:10.1164/rccm.201706-1172OC

http://www.ncbi.nlm.nih.gov/pubmed/29161116

26.

Hung

IFN.

KKW.

Lee

C-K

et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144(2):464-473.doi:10.1378/chest.12-2907

http://www.ncbi.nlm.nih.gov/pubmed/23450336

27.

Kim

H-Y.

E-Y.

Park

et al. Medicinal herbal extracts of Sophorae radix, Acanthopanacis cortex, Sanguisorbae radix and Torilis fructus inhibit coronavirus replication in vitro. Antivir Ther. 2010;15(5):697-709.doi:10.3851/IMP1615

http://www.ncbi.nlm.nih.gov/pubmed/20710051

28.

Yang

C-W.

Lee

Y-Z.

Kang

I-J

et al. Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus. Antiviral Res. 2010;88(2):160-168.doi:10.1016/j.antiviral.2010.08.009

http://www.ncbi.nlm.nih.gov/pubmed/20727913

29.

Dudani

Saraogi

. Use of herbal medicines on coronavirus. Act Scie Pharma. 2020;4(4):61-63.doi:10.31080/ASPS.2020.04.0518

30.

Yang

J-L.

TKQ.

. Discovery of inhibitory materials against PEDV corona virus from medicinal plants. Jpn J Vet Res. 2016;64(1):S53-S63.

31.

Cheng

P-W.

L-T.

Chiang

L-C.

Lin

C-C

. Antiviral effects of saikosaponins on human coronavirus 229E in vitro. Clin Exp Pharmacol Physiol. 2006;33(7):612-616.doi:10.1111/j.1440-1681.2006.04415.x

http://www.ncbi.nlm.nih.gov/pubmed/16789928

32.

Kim

H-Y.

Shin

H-S.

Park

et al. In vitro inhibition of coronavirus replications by the traditionally used medicinal herbal extracts, Cimicifuga rhizoma, Meliae cortex, Coptidis rhizoma, and Phellodendron cortex. J Clin Virol. 2008;41(2):122-128.doi:10.1016/j.jcv.2007.10.011

http://www.ncbi.nlm.nih.gov/pubmed/18036887

33.

Wen

C-C.

Kuo

Y-H.

Jan

J-T

et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem. 2007;50(17):4087-4095.doi:10.1021/jm070295s

http://www.ncbi.nlm.nih.gov/pubmed/17663539

34.

Khaerunnisa

Kurniawan

Awaluddin

Suhartati

Soetjipto

. Potential inhibitor of COVID-19 main protease (mpro) from several medicinal plant compounds by molecular docking study. Preprints. 2020(3):1-14.

35.

Chang

F-R.

Yen

C-T.

Ei-Shazly

et al. Anti-human coronavirus (anti-HCoV) triterpenoids from the leaves of Euphorbia neriifolia . Nat Prod Commun. 2012;7(11):1415-1417.doi:10.1177/1934578X1200701103

http://www.ncbi.nlm.nih.gov/pubmed/23285797

36.

Lin

C-W.

Tsai

F-J.

Tsai

C-H

et al. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res. 2005;68(1):36-42.doi:10.1016/j.antiviral.2005.07.002

http://www.ncbi.nlm.nih.gov/pubmed/16115693

37.

Yuan

et al. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol. 2004;78(20):11334-11339.doi:10.1128/JVI.78.20.11334-11339.2004

http://www.ncbi.nlm.nih.gov/pubmed/15452254

38.

Fung

KP.

Leung

PC.

Tsui

KWS

et al. Immunomodulatory activities of the herbal formula Kwan Du Bu Fei Dang in healthy subjects: a randomised, double-blind, placebo-controlled study. Hong Kong Med J. 2011;17(Suppl 2):41-43.http://www.ncbi.nlm.nih.gov/pubmed/21368336

39.

Schwarz

Sauter

Wang

et al. Kaempferol derivatives as antiviral drugs against the 3A channel protein of coronavirus. Planta Med. 2014;80(2-3):177-182.doi:10.1055/s-0033-1360277

http://www.ncbi.nlm.nih.gov/pubmed/24458263

40.

T-Y.

S-L.

Chen

J-C.

C-C.

Hsiang

C-Y

. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2007;74(2):92-101.doi:10.1016/j.antiviral.2006.04.014

http://www.ncbi.nlm.nih.gov/pubmed/16730806

41.

Chen

C-J.

Michaelis

Hsu

H-K

et al. Toona sinensis Roem tender leaf extract inhibits SARS coronavirus replication. J Ethnopharmacol. 2008;120(1):108-111.doi:10.1016/j.jep.2008.07.048

http://www.ncbi.nlm.nih.gov/pubmed/18762235

42.

Luo

Gong

et al. Anti-SARS coronavirus 3C-like protease effects of Rheum palmatum L. extracts. Biosci Trends. 2009;3(4):124-126.http://www.ncbi.nlm.nih.gov/pubmed/20103835

43.

Kim

Shin

DH.

Kim

M-S

. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem. 2020;35(1):145-151.doi:10.1080/14756366.2019.1690480

http://www.ncbi.nlm.nih.gov/pubmed/31724441

44.

Nguyen

TTH.

Woo

H-J.

Kang

H-K

et al. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris. Biotechnol Lett. 2012;34(5):831-838.doi:10.1007/s10529-011-0845-8

http://www.ncbi.nlm.nih.gov/pubmed/22350287

45.

Kim

Shin

DH.

Kim

M-S

. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors. Chem Biol Drug Des. 2019;94(6):2023-2030.doi:10.1111/cbdd.13604

http://www.ncbi.nlm.nih.gov/pubmed/31436895

46.

M-S.

Lee

et al. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorg Med Chem Lett. 2012;22(12):4049-4054.doi:10.1016/j.bmcl.2012.04.081

http://www.ncbi.nlm.nih.gov/pubmed/22578462

47.

Kim

DE.

Min

JS.

Jang

et al. Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells. Biomolecules. 2019;9(11):696-16.doi:10.3390/biom9110696

http://www.ncbi.nlm.nih.gov/pubmed/31690059

Coronavirus Treatments: What Drugs Might Work Against COVID-19?

Abstract

Keywords

Material and Methods

Data Collection

Results and Discussion

Evidence of Conventional Treatment of Human Coronaviruses

Medicinal Plants or Their Constituents for the Treatment of Coronavirus Infection

Conclusion

Footnotes

Declaration of Conflicting Interests

Funding

ORCID iD

References